Dr. Reddy’s inks strategic deal for 8 injectables with Gland Pharma

HYDERABAD, INDIA and PRINCETON, N.J. — Dr. Reddy’s Laboratories and Gland Pharma have announced a strategic collaboration to market and distribute eight injectable generics. 

 

The portfolio includes hospital- and clinic-administered products for which abbreviated new drug applications (ANDAs) have been filed, and some whose ANDAs will be filed imminently, the companies said. The combined U.S. sales of the drugs for 12 months ending August 2016 were about $1 billion, according to IMS Health moving annual total data. 

 

“We are excited about this opportunity. Dr. Reddy’s Laboratories has a strong track record in developing, marketing and distributing generic injectables in the U.S.,” Dr. Reddy’s EVP and head of North America Alok Sonig said. “Our strengths, combined with Gland’s track record of manufacturing and operational excellence, will help bring affordable medications within reach of patients and complement our specialty injectables offering in the short-to-medium term.”

 

Dr. Reddy’s has been developing its injectable business in the United States, recently launching a generic of Zemplar (paricalcitol) injection. 

 

“We are happy to expand our collaboration with Dr. Reddy’s for marketing and distribution of Gland Products in US and other Ex-U.S. markets,” Gland Pharma COO Srinivas Sadu said. “Dr. Reddy’s has an impressive track record of commercializing injectables products in the U.S., and we are confident that our partnership will continue to grow.”